$OSTX 🚀👀 🔹️ FDA accepted a new meeting request to review the company's patent-pending OST-HER2 biomarker data, another step toward a potential BLA submission

$OSTX 🚀👀 🔹️ FDA accepted a new meeting request to review the company's patent-pending OST-HER2 biomarker data, another step toward a potential BLA submission. 🔹️ Type B FDA meetings with both CDER and CBER are expected as the company prepares for Accelerated Approval. 🔹️ Interim 3-year overall …